Journal article

Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial.

John R Petrie, Nish Chaturvedi, Ian Ford, Irene Hramiak, Alun D Hughes, Alicia J Jenkins, Barbara E Klein, Ron Klein, Teik Chye Ooi, Peter Rossing, Naveed Sattar, Coen DA Stehouwer, Helen M Colhoun, undefined REMOVAL Trial Team

Diabetes Obes Metab | Published : 2017

Abstract

AIMS: Cardiovascular (CV) disease is a major cause of reduced life expectancy in type 1 diabetes (T1D). Intensive insulin therapy prevents CV complications but is constrained by hypoglycaemia and weight gain. Adjunct metformin reduces insulin dose requirement and stabilizes weight but there are no data on its cardiovascular effects. We have therefore initiated an international double-blind, randomized, placebo-controlled trial (REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to examine whether metformin reduces progression of atherosclerosis in adults with T1D. Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 specified CV ris..

View full abstract